Immunoscintigraphy of venous thrombi: Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody

Massimo Ciavolella, Rosanna Tavolaro, Mario Di Loreto, Filippo La Torre, Alessia Nicolai, Orazio Schillaci, Maria Ierardi, Francesco Scopinaro

Research output: Contribution to journalArticle

Abstract

Safety and thrombus imaging capabilities of the 99mTc-labeled form of a new F(ab')2 monoclonal antibody (MoAb) against fragment D dimers from cross-linked human fibrin, previously shown to be effective labeled to 131I in detecting venous thrombi in the rabbit, were investigated. Sixteen patients (seven men, mean age: 60 ± 7 years) with deep (n = three) and superficial (n = 13) venous thromboses of the lower limbs documented at echo- Doppler study underwent, 24 hours before saphenous vein stripping, a scintigraphic study after IV injection of the 99mTc-MoAb (1,129 ± 275 MBq/mL), acquiring dynamic images, as well as early and delayed static images of lower limbs. Tracer activity was compared in normal and pathologic areas. At the operation, vessel wall including the thrombotic lesion was isolated, weighed, and counted. Blood radioactivity and MoAb concentration were also measured. No adverse reaction was observed after MoAb administration. Thrombus site appeared as a focal area (hot spot) of asymmetrically increased tracer uptake, already detectable at early images in all patients. All thrombi detected at echo-Doppler study (n=25) were confirmed at scintigraphic study, which showed four additional hot spots subsequently confirmed to represent thrombi at operation. Average percent ratio between pathologic and normal regions was 1.51 ± 1.34 (p <0.05) at time-activity curves, 2.27 ± 1.1 (p <0.05) at early static images, and 2.15 ± 1.2 (p <0.05) at delayed images, respectively. Thrombus-to-blood uptake ratio was 4.3 ± 0.9 (p <0.01). The F(ab')2 MoAb proved to be safe, and low levels of antimouse antibodies were detected in response, although further studies are needed to assess tolerance and effectiveness in case of a second administration in the same patient. The 99mTc-labeled MoAb was very effective in identifying venous thromboses both at deep and superficial localizations, although its sensitivity and specificity need be evaluated in a more numerous group, including also patients with different and clinically more relevant localizations, such as caval thromboses. However, the possibility of obtaining high-quality images within 4 hours of MoAb administration is clinically relevant, and carries also therapeutic implications, especially in pulmonary thromboembolism.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalAngiology
Volume50
Issue number2
Publication statusPublished - Feb 1999

Fingerprint

Thrombosis
Monoclonal Antibodies
Venous Thrombosis
Lower Extremity
Immunoglobulin Fragments
Venae Cavae
Saphenous Vein
fibrin fragment D
Fibrin
Pulmonary Embolism
Radioactivity
Rabbits
Safety
Sensitivity and Specificity
Injections
Antibodies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ciavolella, M., Tavolaro, R., Di Loreto, M., La Torre, F., Nicolai, A., Schillaci, O., ... Scopinaro, F. (1999). Immunoscintigraphy of venous thrombi: Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody. Angiology, 50(2), 103-109.

Immunoscintigraphy of venous thrombi : Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody. / Ciavolella, Massimo; Tavolaro, Rosanna; Di Loreto, Mario; La Torre, Filippo; Nicolai, Alessia; Schillaci, Orazio; Ierardi, Maria; Scopinaro, Francesco.

In: Angiology, Vol. 50, No. 2, 02.1999, p. 103-109.

Research output: Contribution to journalArticle

Ciavolella, M, Tavolaro, R, Di Loreto, M, La Torre, F, Nicolai, A, Schillaci, O, Ierardi, M & Scopinaro, F 1999, 'Immunoscintigraphy of venous thrombi: Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody', Angiology, vol. 50, no. 2, pp. 103-109.
Ciavolella M, Tavolaro R, Di Loreto M, La Torre F, Nicolai A, Schillaci O et al. Immunoscintigraphy of venous thrombi: Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody. Angiology. 1999 Feb;50(2):103-109.
Ciavolella, Massimo ; Tavolaro, Rosanna ; Di Loreto, Mario ; La Torre, Filippo ; Nicolai, Alessia ; Schillaci, Orazio ; Ierardi, Maria ; Scopinaro, Francesco. / Immunoscintigraphy of venous thrombi : Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody. In: Angiology. 1999 ; Vol. 50, No. 2. pp. 103-109.
@article{81d64941c67d4f6eb7f8227c451a1fa0,
title = "Immunoscintigraphy of venous thrombi: Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody",
abstract = "Safety and thrombus imaging capabilities of the 99mTc-labeled form of a new F(ab')2 monoclonal antibody (MoAb) against fragment D dimers from cross-linked human fibrin, previously shown to be effective labeled to 131I in detecting venous thrombi in the rabbit, were investigated. Sixteen patients (seven men, mean age: 60 ± 7 years) with deep (n = three) and superficial (n = 13) venous thromboses of the lower limbs documented at echo- Doppler study underwent, 24 hours before saphenous vein stripping, a scintigraphic study after IV injection of the 99mTc-MoAb (1,129 ± 275 MBq/mL), acquiring dynamic images, as well as early and delayed static images of lower limbs. Tracer activity was compared in normal and pathologic areas. At the operation, vessel wall including the thrombotic lesion was isolated, weighed, and counted. Blood radioactivity and MoAb concentration were also measured. No adverse reaction was observed after MoAb administration. Thrombus site appeared as a focal area (hot spot) of asymmetrically increased tracer uptake, already detectable at early images in all patients. All thrombi detected at echo-Doppler study (n=25) were confirmed at scintigraphic study, which showed four additional hot spots subsequently confirmed to represent thrombi at operation. Average percent ratio between pathologic and normal regions was 1.51 ± 1.34 (p <0.05) at time-activity curves, 2.27 ± 1.1 (p <0.05) at early static images, and 2.15 ± 1.2 (p <0.05) at delayed images, respectively. Thrombus-to-blood uptake ratio was 4.3 ± 0.9 (p <0.01). The F(ab')2 MoAb proved to be safe, and low levels of antimouse antibodies were detected in response, although further studies are needed to assess tolerance and effectiveness in case of a second administration in the same patient. The 99mTc-labeled MoAb was very effective in identifying venous thromboses both at deep and superficial localizations, although its sensitivity and specificity need be evaluated in a more numerous group, including also patients with different and clinically more relevant localizations, such as caval thromboses. However, the possibility of obtaining high-quality images within 4 hours of MoAb administration is clinically relevant, and carries also therapeutic implications, especially in pulmonary thromboembolism.",
author = "Massimo Ciavolella and Rosanna Tavolaro and {Di Loreto}, Mario and {La Torre}, Filippo and Alessia Nicolai and Orazio Schillaci and Maria Ierardi and Francesco Scopinaro",
year = "1999",
month = "2",
language = "English",
volume = "50",
pages = "103--109",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Immunoscintigraphy of venous thrombi

T2 - Clinical effectiveness of a new antifibrin D-dimer monoclonal antibody

AU - Ciavolella, Massimo

AU - Tavolaro, Rosanna

AU - Di Loreto, Mario

AU - La Torre, Filippo

AU - Nicolai, Alessia

AU - Schillaci, Orazio

AU - Ierardi, Maria

AU - Scopinaro, Francesco

PY - 1999/2

Y1 - 1999/2

N2 - Safety and thrombus imaging capabilities of the 99mTc-labeled form of a new F(ab')2 monoclonal antibody (MoAb) against fragment D dimers from cross-linked human fibrin, previously shown to be effective labeled to 131I in detecting venous thrombi in the rabbit, were investigated. Sixteen patients (seven men, mean age: 60 ± 7 years) with deep (n = three) and superficial (n = 13) venous thromboses of the lower limbs documented at echo- Doppler study underwent, 24 hours before saphenous vein stripping, a scintigraphic study after IV injection of the 99mTc-MoAb (1,129 ± 275 MBq/mL), acquiring dynamic images, as well as early and delayed static images of lower limbs. Tracer activity was compared in normal and pathologic areas. At the operation, vessel wall including the thrombotic lesion was isolated, weighed, and counted. Blood radioactivity and MoAb concentration were also measured. No adverse reaction was observed after MoAb administration. Thrombus site appeared as a focal area (hot spot) of asymmetrically increased tracer uptake, already detectable at early images in all patients. All thrombi detected at echo-Doppler study (n=25) were confirmed at scintigraphic study, which showed four additional hot spots subsequently confirmed to represent thrombi at operation. Average percent ratio between pathologic and normal regions was 1.51 ± 1.34 (p <0.05) at time-activity curves, 2.27 ± 1.1 (p <0.05) at early static images, and 2.15 ± 1.2 (p <0.05) at delayed images, respectively. Thrombus-to-blood uptake ratio was 4.3 ± 0.9 (p <0.01). The F(ab')2 MoAb proved to be safe, and low levels of antimouse antibodies were detected in response, although further studies are needed to assess tolerance and effectiveness in case of a second administration in the same patient. The 99mTc-labeled MoAb was very effective in identifying venous thromboses both at deep and superficial localizations, although its sensitivity and specificity need be evaluated in a more numerous group, including also patients with different and clinically more relevant localizations, such as caval thromboses. However, the possibility of obtaining high-quality images within 4 hours of MoAb administration is clinically relevant, and carries also therapeutic implications, especially in pulmonary thromboembolism.

AB - Safety and thrombus imaging capabilities of the 99mTc-labeled form of a new F(ab')2 monoclonal antibody (MoAb) against fragment D dimers from cross-linked human fibrin, previously shown to be effective labeled to 131I in detecting venous thrombi in the rabbit, were investigated. Sixteen patients (seven men, mean age: 60 ± 7 years) with deep (n = three) and superficial (n = 13) venous thromboses of the lower limbs documented at echo- Doppler study underwent, 24 hours before saphenous vein stripping, a scintigraphic study after IV injection of the 99mTc-MoAb (1,129 ± 275 MBq/mL), acquiring dynamic images, as well as early and delayed static images of lower limbs. Tracer activity was compared in normal and pathologic areas. At the operation, vessel wall including the thrombotic lesion was isolated, weighed, and counted. Blood radioactivity and MoAb concentration were also measured. No adverse reaction was observed after MoAb administration. Thrombus site appeared as a focal area (hot spot) of asymmetrically increased tracer uptake, already detectable at early images in all patients. All thrombi detected at echo-Doppler study (n=25) were confirmed at scintigraphic study, which showed four additional hot spots subsequently confirmed to represent thrombi at operation. Average percent ratio between pathologic and normal regions was 1.51 ± 1.34 (p <0.05) at time-activity curves, 2.27 ± 1.1 (p <0.05) at early static images, and 2.15 ± 1.2 (p <0.05) at delayed images, respectively. Thrombus-to-blood uptake ratio was 4.3 ± 0.9 (p <0.01). The F(ab')2 MoAb proved to be safe, and low levels of antimouse antibodies were detected in response, although further studies are needed to assess tolerance and effectiveness in case of a second administration in the same patient. The 99mTc-labeled MoAb was very effective in identifying venous thromboses both at deep and superficial localizations, although its sensitivity and specificity need be evaluated in a more numerous group, including also patients with different and clinically more relevant localizations, such as caval thromboses. However, the possibility of obtaining high-quality images within 4 hours of MoAb administration is clinically relevant, and carries also therapeutic implications, especially in pulmonary thromboembolism.

UR - http://www.scopus.com/inward/record.url?scp=0033018954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033018954&partnerID=8YFLogxK

M3 - Article

C2 - 10063940

AN - SCOPUS:0033018954

VL - 50

SP - 103

EP - 109

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 2

ER -